Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) will present a corporate update in a fireside chat at the Jefferies Global Healthcare Conference in New York.
The presentation is scheduled for Wednesday, June 3, 2026, from 9:55–10:25 a.m. ET, with a live webcast and 30-day replay on the Vor Bio investor website.
Positive
- None.
Negative
- None.
News Market Reaction – VOR
In the May 28 session, VOR declined 3.29%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | Phase 3 data update | Positive | -5.3% | Interim Phase 3 TELIGAN data in IgA nephropathy published in NEJM. |
| May 13 | Quarterly earnings | Neutral | -3.4% | Q1 2026 results and corporate update with cash runway into early 2029. |
| May 04 | Inducement grants | Neutral | +5.5% | Inducement stock options and RSUs granted to six new employees. |
| Apr 01 | Inducement grants | Neutral | +3.8% | Additional inducement options and RSUs granted to new hires. |
| Mar 30 | Earnings & financing | Neutral | +1.5% | Q4 and 2025 results plus a $75M private placement and cash update. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows negative reactions to fundamental updates (clinical and earnings) but positive moves on routine corporate items like inducement grants.
Over the past few months, Vor Bio has reported multiple milestones, including interim Phase 3 TELIGAN data in IgA nephropathy (May 14, 2026) and Q1 2026 results with $491.5 million in cash and investments (May 13, 2026). Earlier, it disclosed repeated inducement equity grants in April and May 2026 and Q4 2025/full-year 2025 results noting a $75.0 million private placement and pro-forma cash of $530.2 million. Against this backdrop, the Jefferies conference appearance is a routine visibility event rather than a new financial or clinical catalyst.
Key Terms
autoimmune diseases medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corporate update in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY.
Presentation: Wednesday, June 3, 2026 at 9:55am – 10:25 am ET
A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com. A replay of the webcast will be available on the Vor website for approximately 30 days following the presentation.
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Media & Investor Contacts: Carl Mauch cmauch@vorbio.com